Abstract:Abstract Multiple myeloma (MM) is a bone marrow-based malignancy that has a range of consequences resulting from either its direct effects on the bone marrow microenvironment- causing anaemia, more extensive myelosuppression and bone lysis - or its indirect effects on the kidney and other organ systems. Over the past several years, the introduction of autologous stem cell transplantation, immunomodulatory drugs, proteasome inhibitors, histone deacetylase inhibitors, and monoclonal antibodies has substantially improved survival outcomes. However, MM remains biologically heterogeneous with significant variability among patients in terms of clinical features, response to therapy and overall survival (OS). Several prognostic variables can help predict this variability in outcomes ranging from clinical based systems such as the International Staging System (ISS) to more advanced molecular characterizations of the myeloma PCs by cytogenetics and gene expression profiling. However with the advancement in technology utilized for laboratory testing and the emergence of new treatments for MM, there has been an evolution in the significance of these previously defined prognostic markers with time. Assessment of disease activity and depth of response continues to be a moving target in MM. Super-resolution fluorescence imaging is a major breakthrough in the field of optical imaging in this century. Super-resolution fluorescence imaging has been applied to a variety of biological imaging applications, including membrane, cytoskeletal and cytosolic proteins in fixed and living cells. Molecular motions can be quantified. To establish the detection limit and sensitivity threshold of dSTORM and FC, we used serial dilutions of anti-CD38 antibody to detect expression of CD38 on 8226 cells by Super Resolution localization Microscopy and flow cytometry (FC). Design six different antibody concentrations (300ng/ml, 30ng/ml, 10ng/ml, 3ng/ml, 1ng/ml, 0.3ng/ml) to label MM cells with immunofluorescence, and then detect them by flow cytometry. Similarly, design eight different antibody concentrations (1μg/ml, 300ng/ml, 30ng/ml, 10ng/ml, 3ng/ml, 1ng/ml, 0.3ng/ml, 0.1ng/ml), and perform the same treatment, perform immunofluorescence labeling on MM cells, and then perform super-resolution imaging, and calculate the density of CD38 protein on the surface of MM cells of each concentration. Figure 1A detects the ratio of the number of cells to the total number of cells, it can be seen from Figure 1A that when the antibody concentration is not less than 30ng/ml, almost all MM thinners can detect the signal, but when the antibody concentration is less than at 30ng/ml, only a few or no cells can detect the signal. This shows that when the antibody concentration is lower than 30ng/ml, the sensitivity of flow cytometry is no longer sufficient to detect CD38 protein on the surface of MM cells. From Figure 1B, it can be seen that even when the CD38 antibody concentration is 0.3ng/ml, super-resolution imaging can still accurately identify each CD38 antigen molecule on the surface of MM cells, and the statistical CD38 protein density is 8.5864±1.4180/μm2. This shows that the sensitivity of super-resolution is much higher than that of streaming. Disclosures No relevant conflicts of interest to declare.

[Immunophenotypic Characteristics of Multiple Myeloma Cells].

Immunophenotype and its clinical significant of multiple myeloma

The Detection of the Immunophenotyping of Plasma Cells in Patients with Multiple Myeloma

Immunophenotype Characteristics of Patients with Multiple Myeloma in Different Risk Stratification

Clinical Implications of C-Maf Expression in Plasma Cells from Patients with Multiple Myeloma

The Hematopoietic Stem Cell Antigen, CD34, is Not Expressed on the Malignant Cells in Multiple Myeloma

[Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases]

Expressions of CD40 and CD138 on surface of myeloma cells

Expression of CD56 and CD19 in Patients with Newly Diagnosed Multiple Myeloma and Their Relationship with Karyotypes and Prognosis

Recent Advances on the Prognostic Value of Immunophenotyping in Multiple Myeloma by Flow Cytometry——Review

Application of bone marrow cell immunophenotyping analysis in diagnosing and monitoring of multiple myeloma

[Immunophenotypes in 115 Patients with Acute Myeloid Leukemia by Multi-Color Flow Cytometry].

Lymphocyte profile in peripheral blood of patients with multiple myeloma

[Bone Marrow Morphology of Multiple Myeloma with Non-bone-related Extramedullary Disease].

Changes of Peripheral Blood Lymphocyte Subsets and Cytokines in Patients with Multiple Myeloma and Their Clinical Significance

Super Resolution Localization Microscopy Enables Quantitative Diagnosis of Multiple Myeloma

Clinical and immunological characteristics of high-risk double-hit multiple myeloma

The Expression Of Cd200 As A Prognostic Factor In Newly Diagnosed Multiple Myeloma

Differential protein expression profile between CD20 positive and negative cells of the NCI-H929 cell line.

Analysis of Tumor Specific Immunoglobulin Gene Rearrangement in Peripheral Blood B-cells of Multiple Myeloma Patients by a PCR-SSCP Method.

The clinical significance of lymphocyte subsets in peripheral blood from patients with multiple myeloma